RemeGen Co., Ltd. (RemeGen) has entered into a wealth-management agreement with Oversea-Chinese Banking Corporation Limited (OCBC) to place US$70.00 million of idle self-owned funds in a profit-linked structured deposit. The transaction, approved by the board on 27 March 2026 and executed on 14 May 2026, forms part of the company’s cash-management plan, which permits investments of up to RMB2.50 billion in low- to medium-risk instruments.

The selected product—OCBC Profit-Linked Structured Deposit “Zeng Li” Series (Product Code: SH202605150114PLI)—is classified as a non-principal-guaranteed, fixed-income instrument with a medium risk rating. It is linked to USD bond-linked notes (Series ID0334). The deposit starts accruing on 21 May 2026 and matures on 19 May 2027, although both the subscriber and OCBC retain early-redemption or termination rights. Returns are floating and tied to market performance; no specific yield range was disclosed.

RemeGen’s management cites improved capital-use efficiency and yields above comparable bank time-deposit rates as primary motivations. All terms were negotiated on an arm’s-length basis, and OCBC is confirmed to be an independent third party.

Under Hong Kong Listing Rule 14.07, one applicable percentage ratio for this transaction exceeds 5% but is below 25%, classifying the deal as a discloseable transaction. Consequently, the company is required to report and announce the purchase, though shareholder approval is not mandated.

RemeGen, a PRC-based biopharmaceutical firm focused on innovative biologics for autoimmune, oncology, and ophthalmic diseases, maintains that the agreement aligns with its objective of optimizing returns on temporary surplus cash while adhering to its stated risk parameters.